Lista de obras - Laura Rosanò - Dominio Público Uruguay

Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells.

artículo científico publicado en 2011

Beta-arrestin links endothelin A receptor to beta-catenin signaling to induce ovarian cancer cell invasion and metastasis

scholarly article

Disrupting the endothelin and Wnt relationship to overcome chemoresistance

artículo científico publicado en 2015

Emerging role of the endothelin axis in ovarian tumor progression.

artículo científico publicado en 2005

Endothelin 1 in cancer: biological implications and therapeutic opportunities ⬇️

artículo científico publicado el 25 de julio de 2013

Endothelin A receptor drives invadopodia function and cell motility through the β-arrestin/PDZ-RhoGEF pathway in ovarian carcinoma.

artículo científico publicado en 2015

Endothelin A receptor/β-arrestin signaling to the Wnt pathway renders ovarian cancer cells resistant to chemotherapy

artículo científico publicado en 2014

Endothelin B receptor blockade inhibits dynamics of cell interactions and communications in melanoma cell progression.

artículo científico publicado en 2004

Endothelin axis induces metalloproteinase activation and invasiveness in human lymphatic endothelial cells

scientific article published on 01 August 2010

Endothelin receptor blockade inhibits molecular effectors of Kaposi's sarcoma cell invasion and tumor growth in vivo

artículo científico publicado en 2003

Endothelin therapeutics in cancer: Where are we?

artículo científico publicado en 2016

Endothelin-1 acts as a survival factor in ovarian carcinoma cells

artículo científico publicado en 2002

Endothelin-1 and endothelin-3 promote invasive behavior via hypoxia-inducible factor-1alpha in human melanoma cells

scientific article published on 01 February 2007

Endothelin-1 cooperates with hypoxia to induce vascular-like structures through vascular endothelial growth factor-C, -D and -A in lymphatic endothelial cells.

artículo científico publicado en 2012

Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo.

artículo científico publicado en 2000

Endothelin-1 induces the transactivation of vascular endothelial growth factor receptor-3 and modulates cell migration and vasculogenic mimicry in melanoma cells.

artículo científico publicado en 2012

Endothelin-1 induces tumor proteinase activation and invasiveness of ovarian carcinoma cells

artículo científico publicado en 2001

Endothelin-1 induces vascular endothelial growth factor by increasing hypoxia-inducible factor-1alpha in ovarian carcinoma cells.

artículo científico publicado en 2002

Endothelin-1 inhibits prolyl hydroxylase domain 2 to activate hypoxia-inducible factor-1alpha in melanoma cells

artículo científico publicado en 2010

Endothelin-1 promotes epithelial-to-mesenchymal transition in human ovarian cancer cells

scientific article published on 01 December 2005

Endothelin-1 protects ovarian carcinoma cells against paclitaxel-induced apoptosis: requirement for Akt activation

artículo científico publicado en 2002

Endothelin-1 regulates hypoxia-inducible factor-1α and -2α stability through prolyl hydroxylase domain 2 inhibition in human lymphatic endothelial cells

artículo científico publicado en 2014

Endothelin-1 stimulates cyclooxygenase-2 expression in ovarian cancer cells through multiple signaling pathways: evidence for involvement of transactivation of the epidermal growth factor receptor.

artículo científico publicado en 2004

Endothelin-1 stimulates lymphatic endothelial cells and lymphatic vessels to grow and invade.

artículo científico publicado en 2009

Endothelin-1-induced prostaglandin E2-EP2, EP4 signaling regulates vascular endothelial growth factor production and ovarian carcinoma cell invasion.

artículo científico publicado en 2004

Endothelin-1/endothelin A receptor axis activates RhoA GTPase in epithelial ovarian cancer.

artículo científico publicado en 2016

Endothelin-B receptor blockade inhibits molecular effectors of melanoma cell progression.

artículo científico publicado en 2004

Green tea polyphenol epigallocatechin-3-gallate inhibits the endothelin axis and downstream signaling pathways in ovarian carcinoma

artículo científico publicado en 2006

Induction of ErbB-3 expression by alpha6beta4 integrin contributes to tamoxifen resistance in ERbeta1-negative breast carcinomas

artículo científico publicado en 2008

Integrin-linked kinase functions as a downstream mediator of endothelin-1 to promote invasive behavior in ovarian carcinoma.

artículo científico publicado en 2006

MHC-peptide binding: dimers of cysteine-containing nonapeptides bind with high affinity to HLA-A2.1 class I molecules

artículo científico publicado en 1997

Macitentan blocks endothelin-1 receptor activation required for chemoresistant ovarian cancer cell plasticity and metastasis.

artículo científico publicado en 2016

Nuclear β-arrestin1 is a critical cofactor of hypoxia-inducible factor-1α signaling in endothelin-1-induced ovarian tumor progression.

artículo científico publicado en 2016

Polystyrene beads coated with antibodies directed to HLA class I intracytoplasmic domain: the use in quantitative measurement of peptide-HLA class I binding by flow cytometry.

artículo científico publicado en 2000

Role of endothelin-1 in neovascularization of ovarian carcinoma

artículo científico publicado en 2000

Selective 'in synthesis' labeling of peptides with biotin and rhodamine

artículo científico publicado en 2000

Selective 'in synthesis' labelling of peptides by fluorochromes

scientific article published on 01 July 1997

The endothelin A receptor and epidermal growth factor receptor signaling converge on β-catenin to promote ovarian cancer metastasis.

artículo científico publicado en 2012

The endothelin axis in cancer

artículo científico publicado en 2008

The endothelin axis in cancer: the promise and the challenges of molecularly targeted therapy.

artículo científico publicado en 2008

The interplay between hypoxia, endothelial and melanoma cells regulates vascularization and cell motility through endothelin-1 and vascular endothelial growth factor.

artículo científico publicado en 2014

Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma.

artículo científico publicado en 2003

Understanding and Overcoming Chemoresistance in Ovarian Cancer: Emerging Role of the Endothelin Axis ⬇️

artículo científico publicado el 1 de febrero de 2012

miR-30a inhibits endothelin A receptor and chemoresistance in ovarian carcinoma

artículo científico publicado en 2015

β-Arrestin 1 is required for endothelin-1-induced NF-κB activation in ovarian cancer cells.

artículo científico publicado en 2014

β-arrestin-1 drives endothelin-1-mediated podocyte activation and sustains renal injury

artículo científico publicado en 2013

β-arrestin-1 is a nuclear transcriptional regulator of endothelin-1-induced β-catenin signaling.

artículo científico publicado en 2012

Lista de obras de Laura Rosanò

Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells.

Beta-arrestin links endothelin A receptor to beta-catenin signaling to induce ovarian cancer cell invasion and metastasis

Disrupting the endothelin and Wnt relationship to overcome chemoresistance

Emerging role of the endothelin axis in ovarian tumor progression.

Endothelin 1 in cancer: biological implications and therapeutic opportunities ⬇️

Endothelin A receptor drives invadopodia function and cell motility through the β-arrestin/PDZ-RhoGEF pathway in ovarian carcinoma.

Endothelin A receptor/β-arrestin signaling to the Wnt pathway renders ovarian cancer cells resistant to chemotherapy

Endothelin B receptor blockade inhibits dynamics of cell interactions and communications in melanoma cell progression.

Endothelin axis induces metalloproteinase activation and invasiveness in human lymphatic endothelial cells

Endothelin receptor blockade inhibits molecular effectors of Kaposi's sarcoma cell invasion and tumor growth in vivo

Endothelin therapeutics in cancer: Where are we?

Endothelin-1 acts as a survival factor in ovarian carcinoma cells

Endothelin-1 and endothelin-3 promote invasive behavior via hypoxia-inducible factor-1alpha in human melanoma cells

Endothelin-1 cooperates with hypoxia to induce vascular-like structures through vascular endothelial growth factor-C, -D and -A in lymphatic endothelial cells.

Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo.

Endothelin-1 induces the transactivation of vascular endothelial growth factor receptor-3 and modulates cell migration and vasculogenic mimicry in melanoma cells.

Endothelin-1 induces tumor proteinase activation and invasiveness of ovarian carcinoma cells

Endothelin-1 induces vascular endothelial growth factor by increasing hypoxia-inducible factor-1alpha in ovarian carcinoma cells.

Endothelin-1 inhibits prolyl hydroxylase domain 2 to activate hypoxia-inducible factor-1alpha in melanoma cells

Endothelin-1 promotes epithelial-to-mesenchymal transition in human ovarian cancer cells

Endothelin-1 protects ovarian carcinoma cells against paclitaxel-induced apoptosis: requirement for Akt activation

Endothelin-1 regulates hypoxia-inducible factor-1α and -2α stability through prolyl hydroxylase domain 2 inhibition in human lymphatic endothelial cells

Endothelin-1 stimulates cyclooxygenase-2 expression in ovarian cancer cells through multiple signaling pathways: evidence for involvement of transactivation of the epidermal growth factor receptor.

Endothelin-1 stimulates lymphatic endothelial cells and lymphatic vessels to grow and invade.

Endothelin-1-induced prostaglandin E2-EP2, EP4 signaling regulates vascular endothelial growth factor production and ovarian carcinoma cell invasion.

Endothelin-1/endothelin A receptor axis activates RhoA GTPase in epithelial ovarian cancer.

Endothelin-B receptor blockade inhibits molecular effectors of melanoma cell progression.

Green tea polyphenol epigallocatechin-3-gallate inhibits the endothelin axis and downstream signaling pathways in ovarian carcinoma

Induction of ErbB-3 expression by alpha6beta4 integrin contributes to tamoxifen resistance in ERbeta1-negative breast carcinomas

Integrin-linked kinase functions as a downstream mediator of endothelin-1 to promote invasive behavior in ovarian carcinoma.

MHC-peptide binding: dimers of cysteine-containing nonapeptides bind with high affinity to HLA-A2.1 class I molecules

Macitentan blocks endothelin-1 receptor activation required for chemoresistant ovarian cancer cell plasticity and metastasis.

Nuclear β-arrestin1 is a critical cofactor of hypoxia-inducible factor-1α signaling in endothelin-1-induced ovarian tumor progression.

Polystyrene beads coated with antibodies directed to HLA class I intracytoplasmic domain: the use in quantitative measurement of peptide-HLA class I binding by flow cytometry.

Role of endothelin-1 in neovascularization of ovarian carcinoma

Selective 'in synthesis' labeling of peptides with biotin and rhodamine

Selective 'in synthesis' labelling of peptides by fluorochromes

The endothelin A receptor and epidermal growth factor receptor signaling converge on β-catenin to promote ovarian cancer metastasis.

The endothelin axis in cancer

The endothelin axis in cancer: the promise and the challenges of molecularly targeted therapy.

The interplay between hypoxia, endothelial and melanoma cells regulates vascularization and cell motility through endothelin-1 and vascular endothelial growth factor.

Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma.

Understanding and Overcoming Chemoresistance in Ovarian Cancer: Emerging Role of the Endothelin Axis ⬇️

miR-30a inhibits endothelin A receptor and chemoresistance in ovarian carcinoma

β-Arrestin 1 is required for endothelin-1-induced NF-κB activation in ovarian cancer cells.

β-arrestin-1 drives endothelin-1-mediated podocyte activation and sustains renal injury

β-arrestin-1 is a nuclear transcriptional regulator of endothelin-1-induced β-catenin signaling.